Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis
Therapeutic Advances in Medical Oncology
Published online on June 26, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:The evidence from studies comparing 45 and 30 mg starting doses of first-line dacomitinib for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) remains limited.Objectives:This study aimed to compare the ...
Background:The evidence from studies comparing 45 and 30 mg starting doses of first-line dacomitinib for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) remains limited.Objectives:This study aimed to compare the ...